Target expression details
Target General Information | |||||
---|---|---|---|---|---|
Target ID | T09058 | ||||
Target Name | Trophoblast glycoprotein | ||||
Synonyms | Trophoblast glycoprotein; TPBG | ||||
Target Type | Clinical Trial | ||||
Gene Name | TPBG | ||||
Biochemical Class | Transmembrane protein | ||||
UniProt ID | TPBG_HUMAN | ||||
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
Disease | Prostate cancer | ||||
Example drug | TroVax | Phase 3 | [521911], [1572592] | ||
Tissue | Prostate | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.15 Z-score: 0.17 P-value: 1.30E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
Disease | Lung cancer | ||||
Example drug | CV-9201 | Phase 1/2 | [522696], [1572592] | ||
Tissue | Lung tissue | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 1.07 Z-score: 3.46 P-value: 1.73E-130 |
||||
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section | Fold-change: 1.03 Z-score: 2.77 P-value: 2.39E-66 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
Disease | Breast cancer | ||||
Example drug | Anatumomab mafenatox | Terminated | [528658], [1572592] | ||
Tissue | Breast tissue | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.52 Z-score: 0.82 P-value: 1.21E-24 |
||||
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section | Fold-change: 0.46 Z-score: 0.66 P-value: 8.79E-06 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
Reference | |||||
Ref 528658 | A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74. Epub 2007 Feb 6. | ||||
Ref 521911 | ClinicalTrials.gov (NCT00397345) TroVax Renal Immunotherapy Survival Trial. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.